Compound Evidence File
#EC-2026-0852
LL37
Filed under Peptides. The bureau holds 116 laboratory returns for this compound from 36 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
36 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 7 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 4 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 10.0 | 9.9 | 10.0 | 21 Nov 2025 | 6 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 4 | 10.0 | 10.0 | 10.0 | 4 Apr 2026 | 1 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 10.0 | 9.9 | 10.0 | 1 May 2026 | 5 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 10.0 | 9.9 | 10.0 | 24 Apr 2026 | 6 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 10.0 | 9.9 | 10.0 | 1 Dec 2025 | 20 Apr 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 10.0 | 9.9 | 10.0 | 11 Dec 2025 | 7 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 10.0 | 10.0 | 10.0 | 17 Nov 2025 | 6 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 10.0 | 9.9 | 10.0 | 16 Dec 2025 | 20 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 9.9 | 10.0 | 17 Jun 2026 | 22 Jul 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 3 | 10.0 | 10.0 | 10.0 | 11 May 2026 | 9 Jul 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 3 | 10.0 | 9.9 | 10.0 | 25 Jan 2026 | 14 Apr 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 10.0 | 10.0 | 10.0 | 8 Feb 2026 | 26 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 10.0 | 10.0 | 10.0 | 10 Apr 2026 | 4 Aug 2026 |
| SinoPepCASE #VI-2026-0387 | A | 2 | 10.0 | 10.0 | 10.0 | 19 Jul 2026 | 27 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 10.0 | 10.0 | 10.0 | 2 Jan 2026 | 22 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 9.9 | 9.9 | 10.0 | 1 Nov 2025 | 24 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 9.9 | 9.9 | 10.0 | 18 Feb 2026 | 8 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 9.9 | 9.9 | 10.0 | 13 Dec 2025 | 26 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 9.9 | 9.9 | 10.0 | 11 Feb 2026 | 26 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 9.9 | 9.9 | 9.9 | 1 Apr 2026 | 14 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 9.9 | 9.9 | 9.9 | 22 May 2026 | 24 Jun 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 6 | 9.0 | 8.2 | 9.8 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 6 | 8.8 | 7.4 | 10.0 | 24 May 2026 | 24 May 2026 |
| Golden EagleCASE #VI-2026-0680 | X | 1 | 8.6 | 8.6 | 8.6 | 13 Jun 2025 | 13 Jun 2025 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 6 | 8.5 | 7.1 | 10.0 | 21 May 2026 | 21 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 7 | 8.3 | 7.6 | 8.8 | 21 May 2026 | 21 May 2026 |
| BfflinkCASE #VI-2026-0212 | X | 1 | 8.3 | 8.3 | 8.3 | 20 Jun 2025 | 20 Jun 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 3 | 8.0 | 6.9 | 9.1 | 24 May 2026 | 24 May 2026 |
| InjectifyCASE #VI-2026-0387 | X | 2 | 7.4 | 7.3 | 7.5 | 2 Apr 2025 | 21 May 2026 |
| ZhuoYan labCASE #VI-2026-0902 | X | 2 | 7.2 | 6.9 | 7.5 | 27 Feb 2025 | 17 May 2026 |
| Laicuinuo LCNCASE #VI-2026-0223 | X | 1 | 7.1 | 7.1 | 7.1 | 13 Feb 2025 | 13 Feb 2025 |
| Nuscience PeptidesCASE #VI-2026-0554 | X | 2 | 6.5 | 6.5 | 6.5 | 2 Jul 2025 | 21 May 2026 |
| Xingtai Pukelai Technology CoCASE #VI-2026-0850 | X | 1 | 6.0 | 6.0 | 6.0 | 21 May 2025 | 21 May 2025 |
| Richards Biotech Simply RichardsCASE #VI-2026-0307 | X | 1 | 4.5 | 4.5 | 4.5 | 27 Feb 2025 | 27 Feb 2025 |
Open any subject to view the batch-level evidence for LL37 alone.